|
Oct 17
|
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
|
|
Jul 25
|
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
|
|
Jun 21
|
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
|
|
May 8
|
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
|
|
May 7
|
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
|
|
Apr 8
|
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
|
|
Apr 2
|
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 26
|
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
|
|
Mar 12
|
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
|
|
Feb 26
|
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
|
|
Dec 21
|
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
|
|
Dec 5
|
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
|
|
Aug 7
|
Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)
|